Usage of Roxadustat for treating sepsis

A technology for roxadustat and sepsis, applied in the field of new drug use, which can solve problems such as high fatality rate

Pending Publication Date: 2020-01-24
NANJING CHILDRENS HOSPITAL
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is still a high mortality rate under the current treatment methods, so there

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Usage of Roxadustat for treating sepsis
  • Usage of Roxadustat for treating sepsis
  • Usage of Roxadustat for treating sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1 Roxadustat improves the survival rate of septic mice

[0017] 1 Experimental materials

[0018] The C57BL / 6j mice used in the present invention were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. The Roxadustat used in the present invention was purchased from Selleck Company, and the lipopolysaccharide was purchased from Sigma-Aldrich Company.

[0019] 2 Experimental methods

[0020] 2.1 Mice administration method

[0021] 40 male C57BL / 6j mice (8 weeks old, body weight 22-25g) were fed in an SPF grade animal room, and were randomly divided into control group (n=10) and roxadustat group (n=10) after adaptive feeding for 1 week. 10), lipopolysaccharide group (n=10) and roxadustat+lipopolysaccharide group (n=10).

[0022] Experiment 1: Roxadustat (10 mg / kg / day) was intraperitoneally injected into mice in roxadustat group and roxadustat+lipopolysaccharide group, and PBS was injected intraperitoneally into mice in control group and lipopolysaccha...

Embodiment 2

[0026] Example 2 Roxadustat alleviates the reduction of blood pressure and body temperature in mice caused by sepsis

[0027] 1 Experimental materials

[0028] The C57BL / 6j mice used in the present invention were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. The Roxadustat used in the present invention was purchased from Selleck Company, and the lipopolysaccharide was purchased from Sigma-Aldrich Company.

[0029] 2.1 Mice administration method

[0030] Seventeen male C57BL / 6j mice (8 weeks old, weighing 22-25g) were housed in an SPF animal room, and after one week of adaptive feeding, they were randomly divided into LPS group (n=9) and roxadustat + LPS group Group (n=8). The mice in the roxadustat+lipopolysaccharide group were intraperitoneally injected with roxadustat (10 mg / kg / day), and the mice in the lipopolysaccharide group were injected with PBS intraperitoneally. Two days later, the lipopolysaccharide group and the roxadustat+lipopolysaccharide group...

Embodiment 3

[0037] Example 3 Roxadustat relieves sepsis leading to decreased heart function in mice

[0038] 1 Experimental materials

[0039] The C57BL / 6j mice used in the present invention were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. The Roxadustat used in the present invention was purchased from Selleck Company, and the lipopolysaccharide was purchased from Sigma-Aldrich Company.

[0040] 2 Experimental methods

[0041] 2.1 Mice administration method

[0042] Twenty-eight male C57BL / 6j mice (8 weeks old, weighing 22-25g) were fed in an SPF grade animal room, and were randomly divided into control group (n=6) and roxadustat group (n=6) after adaptive feeding for 1 week. 6), lipopolysaccharide group (n=8) and roxadustat+lipopolysaccharide group (n=8). The mice in the roxadustat group and the roxadustat+lipopolysaccharide group were intraperitoneally injected with roxadustat (10 mg / kg / day), and the mice in the control group and the lipopolysaccharide group were in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to usage of Roxadustat in preparation of drugs for treating sepsis. In order to solve the problem of lack of therapeutic drugs for treating sepsis and organ dysfunction, such asheart dysfunction, liver heart dysfunction and the like, the invention provides novel usage of Roxadustat in preparation of drugs for treating sepsis as well as organ dysfunction, such as heart dysfunction, liver heart dysfunction and the like, thereby effectively reducing fatality rate of sepsis as well as treating organ dysfunction, such as cardiovascular dysfunction, liver dysfunction and the like, caused by sepsis.

Description

Technical field: [0001] The invention belongs to the technical field of new uses of medicines, and in particular relates to the application of Roxadustat in the preparation of medicines for treating sepsis. It specifically relates to the application of roxadustat to play a protective role in sepsis and its complications of heart and liver injury. Background technique: [0002] Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock, defined as sepsis with severe circulatory, cellular, and metabolic disturbances, carries a higher risk of death than sepsis alone. Sepsis and septic shock are important problems facing emergency and critical care medicine. There are more than 19 million sepsis patients every year, and more than 25% of them die, with a high mortality rate. Severe sepsis is accompanied by cardiovascular dysfunction, decreased heart function, decreased blood pressure, and organ dysfunction such as l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/472A61P31/00A61P9/00A61P1/16
CPCA61K31/472A61P31/00A61P9/00A61P1/16
Inventor 夏薇薇贾占军龙广风张爱华黄松明陈红兵李袁媛吴梦颍王倩王皓
Owner NANJING CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap